Journal of Clinical Oncology
Articles in this Issue
Real-world cardiac evaluation in patients with advanced lung cancer who received immune checkpoint inhibitors.
e23360 Background: Cardiac toxicities have been increasingly recognized with the widespread use of cancer immunotherapy. Recent NCCN guideline V1.2025 on...
Dual immune checkpoint inhibition in advanced incurable radioidine-refractory differentiated thyroid carcinoma (RAIR DTC), anaplastic (ATC), and medullary thyroid carcinoma (MTC): Long-term survival results from phase II clinical trial.
6105 Background: Immunoprofiling and preclinical studies with patient derived organotypic tumor spheroids supported therapeutic targeting of programmed de...
Phase I study of oncolytic adenovirus BioTTT001 in patients with peritoneal carcinomatosis.
e14553 Background: The prognosis of secondary peritoneal carcinoma with malignant ascites（MA）is poor, highlighting the urgent need for new therapeutic r...
Quantifying financial toxicity in oncology: A comprehensive analysis of prescription cost disparities using public data from 2022.
1612 Background: Financial toxicity in cancer care poses a significant burden for patients and healthcare systems. This study analyzed public data to eval...
Examination of post-radiation survey data from the navigator-assisted hypofractionation (NAVAH) phase I trial in African-American prostate cancer patients.
e13732 Background: Prostate cancer (PC) is the leading cause of malignancy-related death in men. Per the 2024 Ohio annual cancer report, stratification of...
Determinants of oral cavity cancer recurrence in Pakistan: Findings from a cross-sectional study using an institutional cancer registry.
e18047 Background: Pakistan has a high prevalence of oral cavity cancer (OCC) with a significant recurrence rate. This study aims to explore the factors a...
Lymphoma in sub-Saharan Africa: Report from an oncology centre in Nigeria.
e19038 Background: Lymphomas account for more than half of all hematologic cancers in sub-Saharan Africa (SSA) and were responsible for 10% of cancer-rela...
Cisplatin plus high dose infusional 5-fluorouracil and leucovorin for breast cancer (BC) patients (pts) with hyperbilirubinemia secondary to liver metastases (mets).
e13111 Background: Treatment options for BC with severe hepatic impairment caused by liver mets, i.e., liver visceral crisis, are limited. We evaluated th...
Loss of ANPEP expression may promote the development of aggressive prostate cancer.
e17052 Background: In the era of precision oncology, the development of reliable prognostic biomarkers is essential to facilitate the detection of aggress...
Real-world comparative outcomes of chemo-immunotherapy versus chemotherapy in colon cancer: A multi-center retrospective cohort study.
e15579 Background: Immunotherapy and chemotherapy are key treatments for metastatic colon cancer, but their comparative effects on survival and adverse ev...
“How much does your medication cost?”: Assessing patient attitudes towards the costs of oncology medication to society.
e23040 Background: Global oncology medication expenditure has increased rapidly in recent decades. In many countries, this cost is borne by the healthcare...
Gut dysbiosis as a potential guide for immunotherapy (dis)continuation after 2 years in non-small cell lung cancer: A mono-institutional, multi-omic assessment.
2654 Background: Although most phase II and III clinical trials have set the duration of immune checkpoint blockers (ICB) for advanced non-small cell lung...
The impact of nephrectomy on the clinical outcomes of first-line immunotherapy and tyrosine kinase inhibitors combinations versus sunitinib in advanced renal cell carcinoma: A meta-analysis of randomized studies.
e16505 Background: The treatment paradigm for advanced renal cell carcinoma (RCC) has evolved significantly with the introduction of immune checkpoint inh...
Global practice patterns and outcomes for metastatic uveal melanoma treated regionally versus systemically.
e23324 Background: Due to the hepatotropic pattern of metastasis in uveal melanoma (UM), liver directed therapies (LDT) are commonly used for the treatmen...
Baseline radiological tumor burden to sub-stratify IMDC risk groups in metastatic renal cell carcinoma treated with first-line therapy: A post hoc analysis from a randomized phase III trial.
4544 Background: Baseline radiological tumor burden (BRTB) is a measurement derived from routine CT scans and reflects baseline tumor burden. Herein we as...
Real-world use of antibody drug conjugates (ADCs) in metastatic bladder cancer: Analysis of 10,204 patients treated in clinical practice.
e13525 Background: Metastatic bladder cancer (mBC) is an aggressive disease, with a poor prognosis. Recently, ADCs have emerged as new treatment options,...
SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.
TPS2673 Background: Frequent recurrence and limited long-term survival in unresected or metastatic melanoma after relapse from 1L treatment with a checkpo...
Baseline histopathologic biomarker for predicting frontline immunotherapy combination outcomes in metastatic clear cell renal cell carcinoma (mccRCC).
e16539 Background: The treatment landscape of mccRCC has evolved in recent years, with immune checkpoint inhibitor (ICI) combinations currently serving as...
Neoadjuvant immunotherapy for clinical stage III melanoma: A community cancer center’s experience.
e21561 Background: Several randomized clinical trials have demonstrated enhanced oncologic outcomes with neoadjuvant immunotherapy (IO) for resectable, cl...
A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors.
e14519 Background: The purpose of this study is to determine the safety of autologous TAC T cell administration to subjects with claudin 18.2+ advanced so...
A phase II trial of perioperative oral itraconazole for the management of low risk basal cell carcinoma.
9582 Background: Recently, new treatment options have emerged for advanced basal cell carcinoma (BCC), including oral Hedgehog pathway inhibitors like Vis...
Low-dose chemotherapy and pembrolizumab combined with radiotherapy in the first-line treatment of cT4b esophageal squamous cell carcinoma: A single-arm phase II study.
e16047 Background: Chemotherapy (CT) combined with immune checkpoint inhibitors is the current standard of care in the first-line treatment of metastatic...
Outcomes with neoadjuvant chemotherapy and/or osimertinib in patients with <i>EGFR-</i> mutant resectable non-small cell lung cancers.
8052 Background: There are currently no EGFR -tyrosine kinase inhibitors approved for neoadjuvant treatment of resectable...
Midpoint MRI as an early predictor of responses to neoadjuvant chemotherapy in patients with breast cancer.
e12615 Background: Breast MRI after completion of neoadjuvant chemotherapy (NAC) has demonstrated high sensitivity and positive predictive value in evalua...
Clinical characteristics and prognosis of pulmonary lymphoepithelioma-like carcinoma: A multicentre retrospective study.
8044 Background: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of squamous lung cancer, and large-scale clinical studies on its clinic...